Terms: = Lymphoma AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M AND Prognosis
44 results:
1. Evaluation of Immunohistochemical Expression of ALK-1 in Gliomas, WHO Grade 4 and Its Correlation with idh1-R132H Mutation Status.
Khairy RA; Momtaz EM; Abd El Aziz AM; Shibel PEE
Asian Pac J Cancer Prev; 2024 Jan; 25(1):317-323. PubMed ID: 38285799
[TBL] [Abstract] [Full Text] [Related]
2. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
3. BCL2A1 is associated with tumor-associated macrophages and unfavorable prognosis in human gliomas.
Gao L; Ye Z; Peng S; Lei P; Song P; Li Z; Zhou L; Hua Q; Cheng L; Wei H; Liu J; Cai Q
Aging (Albany NY); 2023 Oct; 15(20):11611-11638. PubMed ID: 37889551
[TBL] [Abstract] [Full Text] [Related]
4. Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review.
Jin X; Liu H; Li J; Xiao X; Yuan X; Chen P; Chen B; Liang Y; Huang F
J Zhejiang Univ Sci B; 2023 Aug; 24(8):711-722. PubMed ID: 37551557
[TBL] [Abstract] [Full Text] [Related]
5.
Babakhanlou R; DiNardo C; Borthakur G
Leuk Lymphoma; 2023; 64(11):1733-1741. PubMed ID: 37462435
[TBL] [Abstract] [Full Text] [Related]
6. [Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma].
Shi YF; Wang HJ; Liu WP; Mi L; Long MP; Liu YF; Lai YM; Zhou LX; Diao XT; Li XH
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Jun; 55(3):521-529. PubMed ID: 37291929
[TBL] [Abstract] [Full Text] [Related]
7. EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.
Chen J; Hong JH; Huang Y; Liu S; Yin J; Deng P; Sun Y; Yu Z; Zeng X; Xiao R; Chan JY; Guan P; Wang Y; Wang P; Liu L; Wen S; Yu Q; Ong CK; Teh BT; Xiong Y; Tan J
Mol Cancer; 2023 May; 22(1):85. PubMed ID: 37210576
[TBL] [Abstract] [Full Text] [Related]
8. Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.
Aldea M; Tagliamento M; Bayle A; Vasseur D; Vergé V; Marinello A; Danlos FX; Blanc-Durand F; Bernard E; Cerbone L; Mosele MF; Renneville A; Hadoux J; Loriot Y; Sakkal M; Vozy A; Sarkozy C; Smolenschi C; Nicotra C; Martin-Romano P; Boccon-Gibod C; Habza W; Lazarovici J; Ponce S; Hollebecque A; Marzac C; Lacroix L; Barlesi F; André F; Besse B; Rouleau E; Italiano A; Micol JB
JCO Precis Oncol; 2023 Mar; 7():e2200583. PubMed ID: 36862966
[TBL] [Abstract] [Full Text] [Related]
9. Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas.
de Pádua Covas Lage LA; Culler HF; Barreto GC; Reichert CO; Levy D; de Oliveira Costa R; Rocha V; Pereira J
Clin Epigenetics; 2022 Dec; 14(1):180. PubMed ID: 36536430
[TBL] [Abstract] [Full Text] [Related]
10. Comprehensive Analysis of the Prognostic Value and Molecular Function of CRNDE in Glioma at Bulk and Single-Cell Levels.
Song L; Li X; Xu X; Huo X; Zheng Y; Wang X; Li D; Zhang J; Wang K; Wang L; Wu Z
Cells; 2022 Nov; 11(22):. PubMed ID: 36429098
[TBL] [Abstract] [Full Text] [Related]
11. Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing.
Hou Y; Zi J; Liu S; Ge Q; Ge Z
Mol Carcinog; 2023 Feb; 62(2):200-209. PubMed ID: 36300887
[TBL] [Abstract] [Full Text] [Related]
12. TET-2 mutations predict poor outcomes and are associated with unfavorable clinical-biological features in PTCL, not otherwise specified and angioimmunoblastic T-cell lymphoma in Brazilian patients.
de Pádua Covas Lage LA; Barreto GC; Culler HF; Cavalcante JB; de Oliveira Alves LB; Nardinelli L; Bendit I; Zerbini MCN; Rocha V; Pereira J
Cancer Biomark; 2022; 35(2):179-191. PubMed ID: 36093687
[TBL] [Abstract] [Full Text] [Related]
13. High Frequency of ASXL1 and idh Mutations in Young Acute Myeloid Leukemia Egyptian Patients.
El Nahass YH; Nader HA; Sabet S; Nooh HA; Bassiony H; Kamel M; Samra MA; Mahmoud HK; El Metnawy WH; El Refaey FA
Asian Pac J Cancer Prev; 2022 Mar; 23(3):977-984. PubMed ID: 35345371
[TBL] [Abstract] [Full Text] [Related]
14. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract] [Full Text] [Related]
15. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and idh1/2 mutations.
Yasuda T; Sanada M; Kawazu M; Kojima S; Tsuzuki S; Ueno H; Iwamoto E; Iijima-Yamashita Y; Yamada T; Kanamori T; Nishimura R; Kuwatsuka Y; Takada S; Tanaka M; Ota S; Dobashi N; Yamazaki E; Hirose A; Murayama T; Sumi M; Sato S; Tange N; Nakamura Y; Katsuoka Y; Sakaida E; Kawamata T; Iida H; Shiraishi Y; Nannya Y; Ogawa S; Taniwaki M; Asou N; Hatta Y; Kiyoi H; Matsumura I; Horibe K; Mano H; Naoe T; Miyazaki Y; Hayakawa F
Blood; 2022 Mar; 139(12):1850-1862. PubMed ID: 34695176
[TBL] [Abstract] [Full Text] [Related]
16. Methylation alterations and advance of treatment in lymphoma.
Liu MK; Sun XJ; Gao XD; Qian Y; Wang L; Zhao WL
Front Biosci (Landmark Ed); 2021 Sep; 26(9):602-613. PubMed ID: 34590470
[TBL] [Abstract] [Full Text] [Related]
17. The clinical and prognostic role of ALK in glioblastoma.
Franceschi E; De Biase D; Di Nunno V; Pession A; Tosoni A; Gatto L; Tallini G; Visani M; Lodi R; Bartolini S; Brandes AA
Pathol Res Pract; 2021 May; 221():153447. PubMed ID: 33887544
[TBL] [Abstract] [Full Text] [Related]
18. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.
Lemonnier F; Safar V; Beldi-Ferchiou A; Cottereau AS; Bachy E; Cartron G; Fataccioli V; Pelletier L; Robe C; Letourneau A; Missiaglia E; Fourati S; Moles-Moreau MP; Delmer A; Bouabdallah R; Voillat L; Becker S; Bossard C; Parrens M; Casasnovas O; Cacheux V; Régny C; Camus V; Delfau-Larue MH; Meignan M; de Leval L; Gaulard P; Haioun C
Blood Adv; 2021 Jan; 5(2):539-548. PubMed ID: 33496747
[TBL] [Abstract] [Full Text] [Related]
19. Germline ALK variations are associated with a poor prognosis in glioma and idh-wildtype glioblastoma.
Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S
J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679
[TBL] [Abstract] [Full Text] [Related]
20. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P; Zhang M
Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
[TBL] [Abstract] [Full Text] [Related]
[Next]
